… COVID-19 … pathways with drugs that can increase the risk of infection in healthy people,
not to mention the implications of such therapy in COVID-19-induced type-1 interferon pathway …

… The COVID-19 may present with mild and moderate disease (… and treatment for COVID-19,
the first therapeutic strategy for … –7)/Mas receptor pathway was inhibited and an imbalance in …

… is associated with increased plasma levels of plasminogen activator inhibitor-1 (PAI-1) (89, …
pathway and inhibition of fibrinolysis by Ang II participate in thrombus formation in COVID-19…

… Here, we show how inhibition of components of the adenosinergic pathway and adenosine
signaling via A 2A R can preserve extracellular ATP, counteract with COVID-19 defensive …

… Small-molecule inhibitors specific to Bruton's tyrosine kinases (BTK) such as acalabrutinib
… for the treatment of COVID-19 due to their ability to inhibit B-cell signalling pathway and …

… act via the JAK-2 and JAK-2 signal transducers with subsequent activation of STAT pathway.
Hence, JAK-inhibitors ruxolitinib and baricitinib have been employed to treat moderate-to-…

… and the metabolic pathway has provided … COVID-19 treatment option. Currently, there are
some clinical trials focussing on stopping ACE inhibitors and ARBs for patients with COVID 19. …

… about the potential use of baricitinib for severe acute respiratory syndrome coronavirus 2 (SARS-…
therapy is an undeniable advantage over other potential inhibitors of the same pathway. …

… that the MAPK signaling pathway is involved in murine coronavirus RNA … inhibit the Raf/MEK/ERK
signaling pathway may be potential antiviral candidates for the treatment of COVID-19. …

… pathways in … pathways in SARS-CoV-2 infection. Whether or not this speculation is confirmed,
the key conclusion from the INBUILD study was that nintedanib therapy appears to inhibit …